Our group has previously investigated the efficacy of Apo2L/TRAIL and CPT-11 combination therapy on patient-derived colon tumors [30] using a SCID mouse xenograft model that our lab has developed [31-34]. Here, TNFSF10 is linked to colonic neoplasm.